Key Points Eli Lilly was second to market with a GLP-1 drug, but it quickly became the industry leader. The company recognizes that patents will only protect its GLP-1 drugs for just so long. The company, like its peers, is always on the lookout for blockbuster new drugs. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has seen huge success in the GLP-1 weight-loss drug space with Mounjaro and Zepbound. Although it was second to market after Novo Nordisk (NYSE: NVO) in the GLP-1 space, better patient outcomes and Novo Nordisk's inability to keep up with demand enabled Eli Lilly to take the industry lead.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.